Y Intercept Hong Kong Ltd Purchases Shares of 5,385 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Y Intercept Hong Kong Ltd purchased a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, Holdings Channel reports. The fund purchased 5,385 shares of the pharmaceutical company’s stock, valued at approximately $2,169,000.

Other hedge funds have also added to or reduced their stakes in the company. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares in the last quarter. Highline Wealth Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $27,000. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $33,000. Brown Lisle Cummings Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $30,000. Finally, Truvestments Capital LLC acquired a new stake in shares of Vertex Pharmaceuticals during the third quarter worth $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on VRTX shares. BMO Capital Markets set a $545.00 target price on Vertex Pharmaceuticals in a report on Friday, January 31st. Bank of America dropped their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a report on Thursday, December 19th. Morgan Stanley lifted their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 11th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $550.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $506.70.

Vertex Pharmaceuticals Stock Performance

Shares of Vertex Pharmaceuticals stock opened at $481.65 on Tuesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market capitalization of $123.68 billion, a P/E ratio of -218.93, a P/E/G ratio of 2.11 and a beta of 0.41. The company’s 50 day moving average price is $436.32 and its two-hundred day moving average price is $460.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 310 shares of Vertex Pharmaceuticals stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares in the company, valued at approximately $29,438,776.43. The trade was a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by company insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.